Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jun 29, 2015 (11 years ago)

HydrOXYzine Hydrochloride Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Tablet/Capsule Specifications; The identification codes on some tablets may be unreadable

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

HydrOXYzine Hydrochloride Tablets, USP 25 mg, Rx only, 100 count (NDC 0603-3968-21), 500 count (NDC 0603-3968-28) and 1000 count (NDC 0603-3968-32) bottles, Manufactured for Qualitest Pharmaceuticals, Huntsville, AL

Affected NDCs 0603-3968-21 0603-3968-28 0603-3968-32

Compare with the code on your package — it is the most precise check available.

Drug: Hydroxyzine

Recalling firm
Qualitest Pharmaceuticals
NDC code
0603-3968-21
Origin
AL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1239-2015 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Hydroxyzine recalls

See all
Class II · Moderate risk

Hydroxyzine Hydrochloride Oral Solution

Failed Impurities/Degradation Specification: OOS for the following - unknown degradant/impurity, 4-chorobenzophenone, and for total impurities.

Terminated Impurity / degradation Morton Grove Pharmaceuticals, Inc. NDC 60432-150-04 D-0174-2021
Class II · Moderate risk

HydrOXYzine HYDROCHLORIDE SYRUP

CGMP Deviations: cleaning procedures during manufacturing caused out of specification results for unknown impurities.

Terminated Impurity / degradation Lannett Company, Inc. NDC 54838-502-80 D-0083-2019

Other recalls by Qualitest Pharmaceuticals

All 2015 recalls
Class III · Low risk

Allopurinol Tablets

Failed Tablet/Capsule Specifications; report of oversized and discolored tablets

Terminated Failed specification Qualitest Pharmaceuticals NDC 0603-2116-28 D-1405-2015
Class III · Low risk

Disulfiram tablets

Failed Dissolution Specifications: During routine stability testing at the 12 month time point, one product lot was found to be out of specification for dissolution.

Terminated Dissolution failure Qualitest Pharmaceuticals NDC 0603-3432-21 D1151-2015
Class III · Low risk

Promethazine Vc With Codeine Syrup

Failed Impurities/Degradation Specifications: A stability lot was out of specification for a known impurity at the 8 month Controlled Room Temperature stability time-point.

Terminated Impurity / degradation Qualitest Pharmaceuticals NDC 0603-1588-54 D00432-2015